findmyKOL
Clinical trialNCT00005487Active, not recruitingObservational

Multi-Ethnic Study of Atherosclerosis (MESA)

SponsorNational Heart, Lung, and Blood Institute (NHLBI)Enrollment6,418AtherosclerosisCardiovascular DiseasesCoronary Artery DiseaseCoronary DiseaseDiabetes MellitusDiabetes Mellitus, Type 2+5 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease (Bild DE et al., Am J Epidemiol 2002; 156(9):871-881). MESA consists of a diverse, community-based sample of an initial 6,814 men and women aged 45-84 years without known cardiovascular disease at baseline. Thirty-eight percent of the recruited participants were White, 28 percent African American, 22 percent Hispanic, and 12 percent of Chinese descent. Participants were recruited from six field centers across the United States: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; New York, New York; and St. Paul, Minnesota. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and heart failure; for cardiovascular disease interventions; and for mortality. The first examination took place over two years, from July 2000 to July 2002, and has been followed by additional examinations. Participants have been contacted every 9 to 12 months throughout the study to assess and adjudicate clinical morbidity and mortality. The study was approved by the Institutional review boards at all participating institutions, and all participants gave written informed consent. In addition, informed consent was obtained for extensive data sharing (dbGaP) and genetic/omic studies, including candidate genes (NHLBI CARe), genome-wide scans (NHLBI SHARe), exome sequencing (NHLBI ESP) and, most recently, the NHLBI TOPMed program.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 1999
Primary completion
31 Dec 2030
Completion
31 Dec 2030
Last update posted
21 Jan 2026
Registered enrollment
6,418
Registry id
NCT00005487

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.